Liquidia (NASDAQ:LQDA) Price Target Raised to $25.00

Liquidia (NASDAQ:LQDA) had its target price increased by Needham & Company LLC from $19.00 to $25.00 in a research report sent to investors on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.

A number of other analysts have also issued reports on LQDA. Wells Fargo & Company began coverage on Liquidia in a research note on Friday, December 20th. They set an “overweight” rating and a $20.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and set a $29.00 price objective on shares of Liquidia in a research note on Thursday. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $26.63.

Liquidia Price Performance

Shares of LQDA opened at $15.12 on Thursday. The firm has a market cap of $1.28 billion, a PE ratio of -9.28 and a beta of 0.07. The stock’s fifty day moving average price is $14.79 and its two-hundred day moving average price is $12.20. Liquidia has a 1 year low of $8.26 and a 1 year high of $16.92.

Liquidia (NASDAQ:LQDA) last issued its earnings results on Wednesday, March 19th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.08). The firm had revenue of $2.92 million during the quarter, compared to the consensus estimate of $4.60 million. Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. Sell-side analysts anticipate that Liquidia will post -1.51 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Liquidia news, General Counsel Russell Schundler sold 16,393 shares of the company’s stock in a transaction dated Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total value of $193,109.54. Following the transaction, the general counsel now directly owns 573,478 shares in the company, valued at $6,755,570.84. This represents a 2.78 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Rajeev Saggar sold 6,249 shares of the company’s stock in a transaction dated Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total value of $73,613.22. Following the completion of the transaction, the insider now owns 270,388 shares in the company, valued at $3,185,170.64. This represents a 2.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 71,245 shares of company stock worth $843,326 in the last ninety days. 30.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Liquidia

A number of institutional investors have recently added to or reduced their stakes in LQDA. California State Teachers Retirement System boosted its holdings in shares of Liquidia by 17.5% in the 4th quarter. California State Teachers Retirement System now owns 51,928 shares of the company’s stock worth $611,000 after purchasing an additional 7,725 shares in the last quarter. Toronto Dominion Bank purchased a new position in shares of Liquidia in the 4th quarter worth about $235,000. Alpine Global Management LLC boosted its holdings in shares of Liquidia by 50.0% in the 4th quarter. Alpine Global Management LLC now owns 150,000 shares of the company’s stock worth $1,764,000 after purchasing an additional 50,000 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Liquidia by 26.9% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 105,734 shares of the company’s stock worth $1,243,000 after purchasing an additional 22,445 shares in the last quarter. Finally, Whitefort Capital Management LP boosted its holdings in shares of Liquidia by 16.8% in the 4th quarter. Whitefort Capital Management LP now owns 1,987,245 shares of the company’s stock worth $23,370,000 after purchasing an additional 285,220 shares in the last quarter. 64.54% of the stock is currently owned by institutional investors.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).